Month: February 2015

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women’s health pharmaceutical company, today announced the approval of LILETTA™ (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration (FDA) for use by women to prevent pregnancy for up to three years. LILETTA is placed in the uterus by a healthcare professional and works by continuously releasing levonorgestrel, a progestin, to prevent pregnancy.

  • Posted in Press Releases
  • Comments Off on Actavis and Medicines360 Announce FDA Approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years